On the other hand, some partial PPARγ agonists decrease weight gain in obesity models [35–37], raising the possibility that their effect on weight would be associated with increased browning of WAT, and even increased thermogenesis. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.